加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.3189
−US$0.0097 · -2.95%
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
常规交易时段
US$0.3189
−US$0.0097 · -2.95%
盘中时间采用ET。市场数据可能有所延迟。
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
日内区间
当前US$0.3189
52周区间
当前US$0.3189
盘中时间采用ET。市场数据可能有所延迟。
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
日内区间
当前US$0.3189
52周区间
当前US$0.3189
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1024.85万 USD | 640.86万 USD | 410.89万 USD | 1045.12万 USD | 138.91万 USD |
| 销售、一般及管理费用 | 281.41万 USD | 243.74万 USD | 320.12万 USD | 66.32万 USD | 29.62万 USD |
| 营业费用 | 1306.27万 USD | 884.59万 USD | 731.01万 USD | 1111.44万 USD | 168.53万 USD |
| 利息收入 | — | — | — | — | 1428 USD |
| 营业利润 | −1306.27万 USD | −884.59万 USD | −731.01万 USD | −1111.44万 USD | −168.53万 USD |
| 净利润 | −1306.35万 USD | −884.76万 USD | −731.17万 USD | −1111.44万 USD | −168.53万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
